Posts
- Category: Articles (continued)
- Prana’s PBT2 presented at the Huntington’s Disease Society of America National Convention
- Predict the onset and course of Huntington's disease
- Premio Nobel per la Fisiologia o Medicina 2012: un approfondimento
- Pride-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease
- PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
- Production of toxic protein causes common neurodegenerative disorder
- Programme Leader: Professor Giovanna Mallucci MD PhD
- Proposed drug may reverse Huntington's disease symptoms
- Protein aggregates save cells during aging
- Proteomic analysis of wild-type and mutant huntingtin associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis
- PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease
- QR Pharma Begins Collaboration on Posiphen and Huntington’s disease
- Quanterix to Host Webinar on Predicting the Progression of Neurodegeneration with a Blood Test
- Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington's disease
- R6/2 Huntington's Disease Mice Develop Early and Progressive Abnormal Brain Metabolism and Seizures
- Rallentare il processo di invecchiamento combatte Alzheimer, Parkinson e Huntington
- Range of brain diseases could be treated by single drug
- Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial
- Raptor Pharmaceutical Completes Enrollment in Phase 2/3 Clinical Trial of RP103 for the Potential Treatment of Huntington's Disease
- Raptor Plans to Advance RP103 in a Registration Study in Huntington's Disease Based on Favorable Treatment Effects at 36 Months in CYST-HD Trial
- Raptor Receives Orphan Drug Designation for Cysteamine Bitartrate in Huntington's Disease From the European Commission
- Rare, Orphan And Neglected Neurodegenerative Diseases - New Research Announced
- Reach2HD, a Phase II study in Huntington's disease, launched
- Reaching out to the ‘HD family’ at the World Congress on Huntington’s Disease
- Reading University team working to beat Huntingdon's disease
- Rebooted neurons halt brain degeneration in mice
- Recent Nature blog on Sangamo and Huntington's disease
- REGENX BIOSCIENCES AND VOYAGER THERAPEUTICS ANNOUNCE LICENSE AGREEMENT
- Research and Markets: Huntington's Disease Global Clinical Trials Review, H2, 2012
- Research Points to Biomarker That Could Track Huntington's Disease Progression
- Research Results from University College Cork Update Knowledge of Small Interference RNAs (siRNAs)
- Research Will Explore New Therapies for Huntington’s Disease
- Research4HD.org founded on May 15, 2012 relaunched October 25, 2012: The first website for direct donations to Huntington’s disease Researchers, Foundations and Clinics.
- Researcher in FAU’s Charles E. Schmidt College of Medicine Receives NIH Grant to Further Investigate and Develop Treatments for Huntington’s Disease
- Researchers develop new compound that slows down progression of Huntington's Disease
- Researchers discover system that reduces neurodegeneration in Huntington’s disease
- Researchers examines whether MRI can improve accuracy of Huntington’s diagnosis
- Researchers find chemical 'switches' for neurodegenerative diseases
- Researchers find controlling element of Huntington’s disease
- Researchers from Pasteur Institute Detail Findings in Neurons
- Researchers get a closer look at how the Huntington's gene works
- Researchers Identify New Links Between Genetic Abnormality and Brain Function in Huntington’s Disease
- Researchers Restore Neuron Function to Brains Damaged by Huntington's Disease
- Restoration of the striatal circuitry: from developmental aspects toward clinical applications
- Results of Auspex Pharmaceuticals' Phase 3 Registration Trial of SD-809 to be Presented at AAN Annual Meeting
- Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate
- Rhenovia files patents for new treatment of Huntington’s disease based on its innovative biosimulation platform
- Rhenovia launches drug discovery for Huntington's disease, others
- Ricerca, cura e assistenza nella Malattia di Huntington: ultimi risultati raggiunti
- RNA Interference's Hot Partnership With Stem Cells
Plugin by dagondesign.com
